Segment Data (Tables)

12 Months Ended

Sep. 30, 2011

Segment Data [Abstract]

Financial information for the Company's segments

Revenues(A)	2011			2010			2009
Medical	$	4,007,304		$	3,796,432		$	3,556,694
Diagnostics		2,480,477			2,318,879			2,226,219
Biosciences		1,341,123			1,257,022			1,203,809
	$	7,828,904		$	7,372,333		$	6,986,722
Segment Operating Income
Medical	$	1,181,404		$	1,118,319		$	1,049,236
Diagnostics		636,361			607,411			607,250
Biosciences		376,389			354,229			362,344
Total Segment Operating Income		2,194,154			2,079,959			2,018,830
Unallocated Expenses(B)		(477,891	)		(418,799	)		(440,239	)(C)
Income From Continuing Operations Before Income Taxes	$	1,716,263		$	1,661,160		$	1,578,591
Segment Assets
Medical	$	3,928,241		$	3,527,457		$	3,706,086
Diagnostics		2,269,797			2,301,586			1,998,490
Biosciences		1,332,246			1,059,774			989,299
Total Segment Assets		7,530,284			6,888,817			6,693,875
Corporate and All Other(D)		2,900,144			2,761,877			2,610,749
	$	10,430,428		$	9,650,694		$	9,304,624
Capital Expenditures
Medical	$	366,915		$	368,857		$	407,884
Diagnostics		93,435			108,941			102,432
Biosciences		37,220			49,821			55,646
Corporate and All Other		17,815			9,687			19,234
	$	515,385		$	537,306		$	585,196
Depreciation and Amortization
Medical	$	248,091		$	253,109		$	243,445
Diagnostics		163,313			163,392			136,690
Biosciences		76,861			72,319			73,067
Corporate and All Other		15,824			13,293			11,402
	$	504,089		$	502,113		$	464,604

(A)	Intersegment revenues are not material.
(B)	Includes primarily interest, net; foreign exchange; corporate expenses; and share-based compensation expense.

(C)	Includes charge associated with the settlement with the direct purchaser plaintiffs (which includes BD’s distributors) in certain antitrust class actions.
(D)	Includes cash and investments and corporate assets.

Revenues by Organizational Units

Revenues by Organizational Units	2011		2010		2009
BD Medical
Medical Surgical Systems	$	2,081,733	$	2,010,009	$	1,889,314
Diabetes Care		866,477		785,759		714,937
Pharmaceutical Systems		1,059,094		1,000,664		952,443
	$	4,007,304	$	3,796,432	$	3,556,694
BD Diagnostics
Preanalytical Systems	$	1,277,793	$	1,197,807	$	1,143,431
Diagnostic Systems		1,202,684		1,121,072		1,082,788
	$	2,480,477	$	2,318,879	$	2,226,219
BD Biosciences
Cell Analysis	$	1,024,445	$	951,238	$	904,517
Discovery Labware		316,678		305,784		299,292
	$	1,341,123	$	1,257,022	$	1,203,809
	$	7,828,904	$	7,372,333	$	6,986,722

Revenue to unaffiliated customers and Long-lived assets including property, plant and equipment

	2011		2010		2009
Revenues
United States	$	3,355,769	$	3,286,565	$	3,130,165
Europe		2,497,278		2,386,965		2,408,319
Asia Pacific		817,323		684,319		563,390
Other		1,158,534		1,014,484		884,848
	$	7,828,904	$	7,372,333	$	6,986,722
Long-Lived Assets
United States	$	3,140,395	$	2,841,639	$	2,469,952
Europe		1,461,085		1,145,043		1,150,655
Asia Pacific		300,006		258,879		231,257
Other		590,544		617,323		537,214
Corporate		270,067		282,560		268,592
	$	5,762,097	$	5,145,444	$	4,657,670